ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Down 20.6% in April

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 460,800 shares, a decline of 20.6% from the March 31st total of 580,600 shares. Approximately 6.1% of the company’s stock are sold short. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is currently 0.2 days.

ZyVersa Therapeutics Price Performance

ZVSA stock opened at $4.99 on Friday. ZyVersa Therapeutics has a twelve month low of $4.44 and a twelve month high of $220.85. The business has a 50 day simple moving average of $7.64 and a 200-day simple moving average of $14.72.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $120.00 price objective on shares of ZyVersa Therapeutics in a research report on Tuesday, March 26th.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases.